Ivonescimab with or without ligufalimab vs pembrolizumab for head and neck cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new immunotherapy combination (ivonescimab alone or with ligufalimab) against the standard immunotherapy pembrolizumab (Keytruda) for people with head and neck cancer that has come back or spread. It may be an option if you have not had any prior immunotherapy and your tumor is PD-L1 positive.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 79 years old.
- Your head and neck cancer has come back or spread and has not been treated with any systemic therapy (chemotherapy, targeted therapy, or immunotherapy) for this stage.
- If you had previous treatment with curative intent (like chemoradiation), your cancer came back more than 6 months after finishing that treatment.
- Your tumor must test positive for a protein called PD-L1 (CPS score of 1 or higher).
- You are fit enough to carry out daily activities – most of the day you are out of bed (ECOG 0 or 1).
- Your blood counts, kidney and liver function are within certain limits (your doctor can check).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two immunotherapy drugs (ivonescimab and pembrolizumab) given with standard chemotherapy before and possibly after surgery for advanced head and neck cancer that can be removed. The aim is to see which drug is better at shrinking the tumor and improving outcomes.
This trial tests a new drug, ivonescimab, combined with chemotherapy for people with advanced mouth or throat cancer that can be removed with surgery. The goal is to see if the combination helps shrink tumors before surgery.
This trial tests a new combination of two immunotherapy drugs (called iparomlimab and tuvonralimab), with or without chemotherapy, for head and neck squamous cell carcinoma that has returned or spread after previous treatment. The goal is to see if this combination can help people with this cancer live longer with fewer side effects.
This study tests a new immunotherapy drug called ivonescimab given before surgery for people with advanced head and neck cancer. The goal is to see if it helps shrink the tumor and improve outcomes.
This Phase 2 study tests pembrolizumab (an immunotherapy medicine) together with induction chemotherapy before the main cancer treatment for stage III/IVA head and neck squamous cell cancer. It aims to improve how well the tumor responds and how long people can stay controlled.
This trial tests whether giving immunotherapy along with chemotherapy before surgery can help treat locally advanced head and neck cancer that can be removed. The goal is to see if this combination shrinks tumors and improves outcomes.
Hear when a new Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.